Atogepant is a second-generation CGRP-blocking drug for migraine prevention that offers a safer liver profile than its predecessors.
2nd-generation gepantAtogepant was designed to avoid the liver toxicity that derailed first-generation CGRP antagonists
What the researchers found
Atogepant is a second-generation CGRP receptor antagonist (gepant) that represents a significant advance in migraine prevention. It works by competitively blocking CGRP receptors, inhibiting trigeminovascular nociception — the pathway directly implicated in migraine pain.
A key advantage over first-generation gepants is its improved safety profile, specifically a reduced risk of liver injury, which was a major limitation of earlier drugs in the class. Atogepant has been approved for the prevention of both episodic and chronic migraine in adults, supported by phase I, II, and III clinical trial data.
Why it matters
Migraine is one of the most common neurological disorders globally and disproportionately affects females. The development of atogepant addresses a long-standing need for preventive treatments that target the underlying biology of migraine rather than just managing symptoms. Its improved hepatic safety profile over first-generation gepants removes a major barrier that limited earlier CGRP antagonists, potentially making this class of drugs accessible to more patients.
How the study worked
This study is a narrative literature review. The authors conducted a comprehensive search of English peer-reviewed articles from PubMed, ClinicalTrials.gov, and other electronic databases. They reviewed key milestones from preclinical studies through phase I, II, and III clinical trials, as well as regulatory approval history, clinical efficacy data, safety profiles, and drug-drug interaction studies.
Who was studied
Adults with episodic and chronic migraine
What this study cannot tell us
As a narrative review, this paper synthesizes existing literature rather than presenting new primary data. The authors highlight that drug-drug interaction studies for atogepant have used insufficiently diverse populations. Since migraine disproportionately affects females, the clinical trial populations may not be fully representative of real-world patients, limiting the generalizability of findings.
How to read the evidence
This is a narrative literature review that synthesizes findings from preclinical and clinical trial data but does not present new primary research. It provides a comprehensive overview with moderate evidence strength, drawing on phase I–III trial results and regulatory approval data.
When this study was published
Published in 2024, this review covers the most current state of atogepant's development and approval status, making it highly relevant to the current migraine treatment landscape.
The bigger picture
The CGRP pathway has become the most important target in modern migraine treatment. Atogepant joins a growing class of drugs — both small-molecule gepants and monoclonal antibodies — that block this pathway. Its development story illustrates how learning from the safety failures of earlier gepants (like telcagepant, which was shelved due to liver concerns) drove the design of safer second-generation molecules. As oral CGRP antagonists become more widely available, they may shift migraine prevention away from repurposed drugs like beta-blockers and antidepressants toward mechanism-specific therapies.
Questions still open
- How does atogepant compare head-to-head with CGRP monoclonal antibodies like erenumab and fremanezumab in long-term prevention?
- Will broader and more diverse clinical trial populations reveal different efficacy or safety profiles in underrepresented groups?
- What are the long-term effects of sustained CGRP receptor blockade with oral gepants taken daily?
Common questions
What makes atogepant different from older migraine prevention drugs?
Is atogepant currently available for patients?
Read the original research
The preclinical discovery and development of atogepant for migraine prophylaxis.
Expert opinion on drug discovery, 19(7), 783-788
Citation
Baraldi, Carlo; Beier, Dagmar; Martelletti, Paolo; Pellesi, Lanfranco. (2024). The preclinical discovery and development of atogepant for migraine prophylaxis.. Expert opinion on drug discovery, 19(7), 783-788. https://doi.org/10.1080/17460441.2024.2365379